Physician profile
Daniel C Goncher
NPI 1629074000
$8,306.25
in general payments reported to CMS, 2019-2025
44 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,758 · 2022: $1,684 · 2023: $1,584 · 2024: $1,725 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,844 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,844.49 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $959.69 | 2021-2025 | |
| Abbvie INC. | $950.04 | 2021-2025 | |
| Novo Nordisk INC | $729.97 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $600.90 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $503.44 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Tactile Systems Technology INC | $474.55 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Abbott Laboratories | $405.80 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $371.55 | 2021-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $302.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.34 | 2021-2025 | Jardiance, Ofev, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $256.58 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $255.09 | 2021-2022 | |
| Exact Sciences Corporation | $226.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.09 | 2021-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $172.37 | 2021-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Goncher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.